PMN 310
Alternative Names: huPMN-310; PMN-310Latest Information Update: 07 Jan 2025
At a glance
- Originator ProMIS Neurosciences
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 13 Dec 2024 ProMis Neurosciences initiates enrolment in the phase I PRECISE-AD trial for Alzheimer's disease in the US (IV) (NCT06750432)
- 30 Oct 2024 Adverse events and pharmacokinetics data from the phase Ia trial in Alzheimer's disease released by ProMIS Neurosciences
- 19 Sep 2024 ProMIS Neurosciences completes a phase-I trial in Alzheimer's disease (In volunteers) in USA (IV) (NCT06105528)